Pharosyn raises $3M seed to speed up pharma’s commercial decisions
Two Cambridge graduates founded Pharosyn in 2025; a year later a top-ten biopharma uses it to cut report work from four hours to 15 minutes. Moonfire just led their $3M seed.
Also see more funding coverage: /category/funding/
Founded 2025 · London, United Kingdom
London-based Pharosyn has raised a $3M seed round led by Moonfire Ventures, with Entrepreneurs First, Transpose Platform and General Advance participating, to expand its AI competitive intelligence platform for pharmaceutical commercial teams.
Pharma is the most data-rich industry in Europe and one of the slowest at reading its own signals – and that gap is exactly where a one-year-old London startup just found its opening. Below, I lay out the round, the company behind it, and why two Cambridge graduates picked one of the least glamorous corners of pharma to build in.
A $3M seed with Moonfire in the lead
Pharosyn announced the $3M seed round on 2 September 2026 (EU-Startups reported the figure at €2.5M). Moonfire Ventures, the London data-driven early-stage fund, led; Entrepreneurs First, Transpose Platform and General Advance joined (Tech Funding News, EU-Startups, 2 Sep 2026).
The money goes into people. The team of eleven will hire engineers and pharmaceutical industry specialists, and push the platform deeper into commercial strategy, portfolio strategy, business development and licensing, market research and forecasting teams – the desks that decide what a drug is worth before it ever ships (use of funds per the company, in Tech Funding News, Sep 2026).
Two Cambridge graduates, eleven people, one top-ten customer
Founded in 2025 by Stephen Cowley (CEO, artificial intelligence at Cambridge) and Joshua Hampson (biochemistry, Cambridge), Pharosyn monitors clinical, regulatory and commercial sources – trial data, licensing deals, hiring trends, epidemiology, even social media – and turns them into traceable reports tailored to a company’s own pipeline. The wider team mixes AI engineering with pharma consulting experience from Citeline and leading consulting firms (EU-Startups, Sep 2026).
The traction is specific. A top-ten biopharmaceutical company already works with the platform, alongside several mid-sized firms across oncology, neurology, immunology and rare diseases. Cowley’s headline number: reports that took four hours now take fifteen minutes, a 94% cut (Tech Funding News, Sep 2026). Pharma is many things; fast is not one of them – which is precisely why that number lands.
An $8.54bn market compounding at 43.55% a year
So how big is the pond these two are fishing in? AI in pharma and biotech is estimated at $8.54bn in 2026 and projected to reach $154.10bn by 2034, a 43.55% CAGR (Fortune Business Insights, updated August 2026). Competitive intelligence is a narrow slice of that, and no reliable sizing exists for the pharma CI segment on its own – but the direction of the whole category is not in doubt.
Europe is doing its share of the funding. EU-Startups counts €75.3M across seven comparable AI and data infrastructure rounds for pharma and biotech in 2026 (EU-Startups, Sep 2026). In our own fundraising data, the same week brought iPremom’s €15M seed for pregnancy diagnostics and Full Health Medical’s €3M raise led by Elkstone in Ireland. Against those, Pharosyn’s $3M is a modest cheque – the kind that buys eighteen months of engineering, not a land grab.
London keeps building pharma’s picks and shovels
The pattern we are seeing: London is becoming the place where health AI gets built for someone else’s market. The imaging story made the point at scale when a London startup raised $220 million to fix American imaging; Pharosyn makes it at seed stage. The incumbents of pharma intelligence built their databases over decades and priced them for the top ten. An AI-native challenger founded in 2025, selling a traceable answer in fifteen minutes, is a bet that the stack gets rebuilt from the workflow up.
The good news is the buyers are already European and global at once – a top-ten biopharma pilot at one year old is rare air for a UK seed. What to watch from here: whether traceability becomes the moat (pharma will not act on an answer it cannot audit), whether the Entrepreneurs First to Moonfire pipeline keeps producing companies this focused, and how quickly the pilot converts into the kind of multi-team contracts the use of funds is clearly aimed at. The AI conference circuit will be full of agents demos this autumn; the revenue is in rooms like these.
The goal was never a European clone of the old intelligence vendors. The goal is the unglamorous layer that helps the world’s most regulated industry decide faster – and Europe is quietly getting good at it. Keep watching the picks and shovels!
